Delayed
London S.E.
10:05:15 29/10/2020 pm IST
|
5-day change
|
1st Jan Change
|
55
GBX
|
+5.77%
|
|
+4.76%
|
-11.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
57.12
|
296.4
|
327.9
|
1,764
|
1,342
|
927.7
|
-
|
-
|
Enterprise Value (EV)
2 |
26.48
|
163.3
|
216.7
|
1,573
|
1,166
|
743.8
|
781.3
|
747.6
|
P/E ratio
|
-1.84
x
|
-3.5
x
|
-7
x
|
-25.1
x
|
-221
x
|
-15.8
x
|
-30.8
x
|
-175
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
10.9
x
|
4,633
x
|
-
|
167
x
|
12.2
x
|
4.01
x
|
EV / Revenue
|
-
|
-
|
7.23
x
|
4,131
x
|
-
|
134
x
|
10.3
x
|
3.23
x
|
EV / EBITDA
|
-6,51,314
x
|
-31,32,464
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-7,81,950
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
13,173
|
57,899
|
66,021
|
81,634
|
85,951
|
81,082
|
-
|
-
|
Reference price
3 |
5.750
|
7.000
|
6.720
|
26.13
|
19.88
|
14.46
|
14.46
|
14.46
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/03/22
|
07/03/23
|
29/02/24
|
-
|
-
|
-
|
1USD in Million2GBP in Million3USD Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
29.97
|
0.3807
|
-
|
5.549
|
76.02
|
231.4
|
EBITDA
|
-40.65
|
-52.14
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-41.08
|
-52.71
|
-54.92
|
-62.96
|
-53.4
|
-106.3
|
-77.42
|
43.97
|
Operating Margin
|
-
|
-
|
-183.28%
|
-16,539.32%
|
-
|
-1,915.49%
|
-101.84%
|
19%
|
Earnings before Tax (EBT)
1 |
-39.21
|
-46.13
|
-41.64
|
-56.89
|
-42.59
|
-102.1
|
-74.15
|
42.07
|
Net income
1 |
-31.94
|
-46.23
|
-41.63
|
-57.1
|
-42.97
|
-103.4
|
-72.89
|
43.23
|
Net margin
|
-
|
-
|
-138.92%
|
-15,000.24%
|
-
|
-1,863.85%
|
-95.88%
|
18.68%
|
EPS
2 |
-3.133
|
-2.000
|
-0.9600
|
-1.040
|
-0.0900
|
-0.9167
|
-0.4700
|
-0.0825
|
Free Cash Flow
|
-33.86
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/03/22
|
07/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.3807
|
-
|
-
|
-
|
-
|
-
|
-
|
3.08
|
5.234
|
8.827
|
14.78
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.33
|
-20.04
|
-16.93
|
-13.08
|
-12.51
|
-17.58
|
-7.845
|
-13.45
|
-15.09
|
-21.73
|
-24.28
|
-28.28
|
-29.66
|
-29.07
|
-27.52
|
Operating Margin
|
-
|
-
|
-
|
-
|
-3,285.81%
|
-
|
-
|
-
|
-
|
-
|
-
|
-918.21%
|
-566.65%
|
-329.26%
|
-186.17%
|
Earnings before Tax (EBT)
1 |
-17.61
|
-19.79
|
-14.6
|
-13.48
|
-8.663
|
-13.12
|
-6.689
|
-12.08
|
-11.21
|
-20.01
|
-23.45
|
-28.83
|
-29.89
|
-27.35
|
-26.24
|
Net income
1 |
-17.43
|
-19.86
|
-14.67
|
-13.53
|
-8.687
|
-13.26
|
-6.933
|
-12.11
|
-11.17
|
-20.61
|
-23.66
|
-29.1
|
-30.16
|
-27.54
|
-26.44
|
Net margin
|
-
|
-
|
-
|
-
|
-2,281.88%
|
-
|
-
|
-
|
-
|
-
|
-
|
-944.64%
|
-576.25%
|
-312.04%
|
-178.82%
|
EPS
2 |
-0.4000
|
-0.4000
|
-0.3200
|
-0.0300
|
-0.1600
|
-0.2400
|
-0.0800
|
-0.1600
|
-0.0200
|
-0.0400
|
-0.1857
|
-0.2300
|
-0.2329
|
-0.1475
|
-0.1400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/03/22
|
03/05/22
|
09/08/22
|
09/11/22
|
07/03/23
|
09/05/23
|
03/08/23
|
02/11/23
|
29/02/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
30.6
|
133
|
111
|
191
|
177
|
184
|
146
|
180
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-33.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.04
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/03/22
|
07/03/23
|
29/02/24
|
-
|
-
|
-
|
Last Close Price
14.46
USD Average target price
35.71
USD Spread / Average Target +146.99% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.20% | 121B | | +19.67% | 113B | | +18.95% | 26.02B | | -23.86% | 19.39B | | -19.03% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|